Suven Life Sciences gets patent approval from New Zealand

| Updated on February 14, 2014

Suven Life Sciences has received patent rights from New Zealand for two products The patents are valid through 2029 and 2030, respectively. The drugs granted patents are used in the treatment of cognitive impairment associated with neurodegenerative disorders, such as Alzheimer, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia. The stock on Friday closed with a marginal gain at ₹72.

Published on February 14, 2014

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor